From interest rate hikes to rising bond yields and persistent inflation, these are all things that could affect the global markets.
Following the stock market opening on Monday, the S&P 500, Dow, and Nasdaq are trading higher at 0.26%, 0.17%, and 0.72%.
Analysts also expect a rate hike of at least 25 basis points at each of the remaining five meetings this year as the Federal Reserve continues its fight against rampant inflation.
China has also not shown any signs of easing lockdown measures despite its impact on the economy and global supply chain.
Furthermore, while the initial buy-in call was from Berkshire’s fund manager, Buffett himself pushed for the additional share purchase.
Although he did clarify that he “doesn’t know what the Justice Department will do.” Nonetheless, this is what he had to say about everything, “If the deal goes through, we make some money, and if the deal doesn’t go through, who knows what happens.” Safe to say, ATVI stock would be in focus today following this notable piece of news.
As it stands, zuranolone is an investigational “two-week, once-daily oral drug,” being developed for the treatment of MDD.
In detail, the company submitted data from two completed studies on zuranolone, the LANDSCAPE and NEST clinical development programs. Speaking on the importance of the drug is Sage CEO Barry Greene.
Whether this can translate to long-term gains for either SAGE stock or BIIB stock remains to be seen.
Prices of penny stocks, cryptocurrencies and other financial instruments are extremely volatile and may be affected by external factors such as financial, promotion, regulatory and political events.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Stockmarket.com and/or the data provider.